Edgewise Therapeutics (EWTX) CMO sells 21,338 shares after option exercise

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Edgewise Therapeutics CMO Joanne M. Donovan exercised stock options to acquire 21,338 shares of common stock at an exercise price of $7.08 per share, then sold 21,338 shares in an open-market transaction at an average price of $32.1168 per share. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on December 26, 2025, meaning the trades were scheduled in advance. After these transactions, she directly holds 9,597 shares of common stock and 153,662 stock options that vest in equal monthly installments over 48 months beginning on September 17, 2023, and expire on August 17, 2033.

Insider Trade Summary 10b5-1

Net Seller: 21,338 shares ($685,308)

Net Sell 3 txns

Insider Donovan Joanne M.

Role CMO

Sold 21,338 shs ($685K)

Type	Security	Shares	Price	Value
Exercise	Stock Option (Right to Buy)	21,338	$0.00	--
Exercise	Common Stock	21,338	$7.08	$151K
Sale	Common Stock	21,338	$32.1168	$685K

Holdings After Transaction: Stock Option (Right to Buy) — 153,662 shares (Direct); Common Stock — 30,935 shares (Direct)

Footnotes (1)

The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote. 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.

Key Figures

Options exercised: 21,338 shares Exercise price: $7.08 per share Shares sold: 21,338 shares +5 more

8 metrics

Options exercised 21,338 shares Stock option exercise on March 31, 2026 at $7.08

Exercise price $7.08 per share Stock Option (Right to Buy) conversion price

Shares sold 21,338 shares Open-market sale on March 31, 2026

Average sale price $32.1168 per share Sales ranged from $32.00 to $32.35

Common shares held after 9,597 shares Direct Edgewise Therapeutics common stock holdings post-transaction

Options held after 153,662 options Stock options remaining outstanding after exercise

Option vesting schedule 1/48th monthly Vesting begins September 17, 2023 while service continues

Option expiration August 17, 2033 Expiration date for the stock option grant

Key Terms

Rule 10b5-1 Plan, Stock Option (Right to Buy, Exercise or conversion of derivative security, open-market sale, +1 more

5 terms

Rule 10b5-1 Plan regulatory

"The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person"

A Rule 10b5-1 plan is a prearranged, written schedule that lets corporate insiders buy or sell company stock at set times or amounts, even if they later learn material nonpublic information. Think of it like setting an automatic thermostat for trades: it creates a clear record that trades were planned in advance, reducing the risk of insider-trading accusations and helping investors trust that insider transactions are routine rather than based on secret information.

Stock Option (Right to Buy financial

"security_title": "Stock Option (Right to Buy)"

Exercise or conversion of derivative security financial

"transaction_code_description": "Exercise or conversion of derivative security""

open-market sale financial

"transaction_action": "open-market sale""

An open-market sale is when a shareholder sells existing shares directly on a public exchange to any willing buyer, rather than through a private deal. Think of it like putting goods on a busy market stall where price is set by supply and demand; for investors it matters because such sales increase available supply, can put short-term downward pressure on the stock price, and signal changes in liquidity or investor confidence.

vesting financial

"1/48th of the shares subject to the option vest each month beginning on September 17, 2023"

Vesting is the process by which you earn full ownership of something, like company stock or a retirement benefit, over time. It’s like earning the right to keep a gift piece by piece the longer you stay with a company, making sure employees stay committed before they receive all the benefits.

Form 4 Insider Transactions: What Each Field Means →

03/31/2026 - 07:33 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Donovan Joanne M.

(Last)

(First)

(Middle)

C/O EDGEWISE THERAPEUTICS, INC.

1715 38TH STREET

(Street)

BOULDER

COLORADO

80301

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Edgewise Therapeutics, Inc. [ EWTX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	CMO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
03/31/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	03/31/2026		M		21,338	A	$7.08	30,935	D
Common Stock	03/31/2026		S⁽¹⁾		21,338	D	$32.1168⁽²⁾	9,597	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
Stock Option (Right to Buy)	$7.08	03/31/2026		M			21,338	⁽³⁾	08/17/2033	Common Stock	21,338	$0.00	153,662	D

Explanation of Responses:

1. The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 Plan adopted by the Reporting Person on December 26, 2025.

2. The price reported in column 4 is an average price. These shares were sold in multiple transactions at prices ranging from $32.00 to $32.35, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

3. 1/48th of the shares subject to the option vest each month beginning on September 17, 2023, subject to the Reporting Person continuing as a service provider through each vest date.

Remarks:

	John R. Moore Attorney-in-Fact for Donovan Joanne M.	03/31/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR

FAQ

What insider transactions did Edgewise Therapeutics (EWTX) report for CMO Joanne Donovan?

CMO Joanne M. Donovan exercised stock options for 21,338 shares at $7.08 and sold 21,338 common shares at an average price of $32.1168. These transactions formed an exercise-and-sell pattern on the same date, according to the Form 4 disclosure.

Was the Edgewise Therapeutics (EWTX) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the sales were effected under a Rule 10b5-1 Plan adopted by Joanne M. Donovan on December 26, 2025. Such plans pre-schedule trades, indicating the timing was determined in advance rather than based on short-term market developments.

At what prices did Edgewise Therapeutics (EWTX) CMO sell her shares?

The Form 4 reports an average sale price of $32.1168 per share. A footnote explains the 21,338 shares were sold in multiple transactions at prices ranging from $32.00 to $32.35, and detailed per-trade information is available upon request.

How many Edgewise Therapeutics (EWTX) shares does the CMO hold after these transactions?

Following the reported transactions, Joanne M. Donovan directly holds 9,597 shares of Edgewise Therapeutics common stock. In addition, she holds 153,662 stock options that remain outstanding after the exercise reported in this Form 4.

What are the key terms of the Edgewise Therapeutics (EWTX) stock options exercised by the CMO?

The exercised stock options entitled Joanne M. Donovan to buy 21,338 shares at $7.08 per share. The option grant covers a larger total amount, with 1/48th of the shares vesting monthly starting September 17, 2023, and an expiration date of August 17, 2033.

What pattern do the Edgewise Therapeutics (EWTX) insider transactions show?

The filing reflects an exercise-and-sell pattern. Joanne M. Donovan exercised options to acquire 21,338 shares, then sold the same number of shares on the open market the same day, while retaining both remaining stock options and a smaller direct common stock position.